Evidence map›Paper›PMID 41345255›Full record

ArticleEuropean journal of human genetics : EJHG2026

Reconsidering a silent variant: SGCA's role in atypical cardiomyopathy.

Smadar Horowitz-Cederboim, Ronit Hoffman-Lipschuetz, Ronen Durst, Shoshi Shpitzen, Ayelet Shauer, Donna R Zwas, Chaggai Rosenbluh, Israel Antman, Avital Eilat, Tamar Harel and 2 more

Abstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Advances in genomic medicine: from diagnosis to patient perspectives.European journal of human genetics : EJHG · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Smadar Horowitz-Cederboim *The Heart Institute, Hadassah Hebrew University Medical Center, Jerusalem, Israel. smadar.horowitz@gmail.com.ORCID 0009-0005-1450-8299
Ronit Hoffman-Lipschuetz *Department of Genetics, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
Ronen Durst *The Heart Institute, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
Shoshi ShpitzenHadassah Center for Cardiogenetics, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
Ayelet ShauerThe Heart Institute, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
Donna R ZwasThe Heart Institute, Hadassah Hebrew University Medical Center, Jerusalem, Israel.ORCID 0000-0003-3025-3941
Chaggai RosenbluhDepartment of Genetics, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
Israel AntmanDepartment of Genetics, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
Avital EilatDepartment of Genetics, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
Tamar HarelDepartment of Genetics, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
Orr TomerThe Heart Institute, Hadassah Hebrew University Medical Center, Jerusalem, Israel.ORCID 0000-0002-3752-1411
Vardiella MeinerDepartment of Genetics, Hadassah Hebrew University Medical Center, Jerusalem, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Limb-girdle muscular dystrophy type R3 (LGMDR3) is caused by pathogenic SGCA variants and typically presents as progressive muscle weakness with limited cardiac manifestations. We investigated five consanguineous families with substantial left ventricular dysfunction, arrhythmias, and life-threatening ventricular tachyarrhythmias. Cardiac assessments, including echocardiography, Holter monitoring, and cardiac magnetic resonance imaging, revealed a spectrum of findings from mild asymptomatic dysfunction to severe dilated cardiomyopathy and malignant arrhythmia requiring implantable cardioverter-defibrillators. Initial evaluation with exome sequencing showed no conclusive results until a genotype-phenotype correlation reanalysis pinpointed a single homozygous synonymous SGCA variant shared by all affected individuals. Despite being distant from canonical splice sites, this variant disrupted normal mRNA splicing, leading to aberrant transcripts and a presumably nonfunctional or structurally altered α-sarcoglycan protein. This study broadens the recognized clinical spectrum of LGMDR3 by revealing significant cardiac involvement and exemplifies how a splice-disrupting synonymous variant, initially classified as likely benign, can underlie a severe cardiac phenotype and merit reclassification. Our findings highlight the importance of integrating genotype-phenotype correlation with functional studies to improve diagnostic accuracy, particularly in underrepresented populations.

Indexed as

CardiomyopathiesSarcoglycansAdolescentAdultChildFemaleHumansMaleMiddle AgedPedigreeSarcoglycans

Identifiers

PMID41345255
PMCPMC13046803

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.